AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN

Disaster Planning/Emergencies DIS

commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises and reauthorization of the Pandemic and All Hazards Preparedness Act

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); White House Office; Defense, Dept of (DOD); Food & Drug Administration (FDA); SENATE

Health Issues HCR

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues

Contacted: Office of Management & Budget (OMB); Defense, Dept of (DOD); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2430 (115th), H.R. 3268 (115th), H.R. 3358 (115th), H.R. 2953 (115th), S. 1603 (115th), S. 870 (115th), H.R. 2066 (115th), S. 1771 (115th)

Medicare/Medicaid MMM

reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services

Contacted: Defense, Dept of (DOD); Office of Management & Budget (OMB); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office

Bills named: H.R. 2953 (115th), S. 1771 (115th), S. 870 (115th), H.R. 3358 (115th), H.R. 2066 (115th)

Budget/Appropriations BUD

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Medicare Laboratory Date of Service Policy; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services, FY19 federal appropriations for FDA, CMS, and HHS related to clinical laboratory service issues

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Defense, Dept of (DOD); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 3268 (115th), H.R. 2066 (115th), S. 1603 (115th), S. 1771 (115th), S. 870 (115th), H.R. 2953 (115th), H.R. 3358 (115th), H.R. 2430 (115th)

Medical/Disease Research/Clinical Labs MED

regulation and oversight of clinical laboratories, including laboratory developed test services, the Diagnostic Accuracy and Innovation Act; reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, TRICARE coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); reauthorization of FDA user fees, FDA Reauthorization Act of 2017 (HR 2430/S 934); narrowing the in-office ancillary services exception to the federal self-referral statute to remove anatomic pathology, advanced diagnostic imaging, physical therapy, and radiation therapy, Promoting Integrity in Medicare Act of 2017 (HR 2066); Preventive Health Savings Act (HR 2953); Medicare physician signature documentation requirements; Creating High Quality Results and Outcomes Necessary to Improve Chronic Care (CHRONIC) Act of 2017 (S. 870); National Diabetes Prevention Program; commercial laboratory surge capacity issues for response to pandemic/epidemic/public health crises; H.R.3268/S.1603, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2018; H.R.3358/S.1771, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2018, Medicare reimbursement of clinical labatory services

Contacted: Office of Management & Budget (OMB); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3268 (115th), S. 1603 (115th), H.R. 2953 (115th), H.R. 2066 (115th), S. 870 (115th), H.R. 3358 (115th), S. 1771 (115th), H.R. 2430 (115th)